Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5456921A · kind A · utility
36Cited by
13References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 1994 |
| Grant date | Oct 10, 1995 |
| Priority date | — |
| Expiry date | Feb 9, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2059
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is concerned with a solid slow release oral pharmaceutical dosage unit which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking agent selected from 2,3 dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of cross-linking agent per 100 g of amylose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.